文献速递甲状腺疾病

韩国低风险甲状腺微小乳头状癌主动监测期间疾病进展:多中心前瞻性队列研究的中期分析

Progression of Low-Risk Papillary Thyroid Microcarcinoma During Active Surveillance: Interim Analysis of a Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma in Korea.
PubMed 文献 · Thyroid · 2022-01-01

该多中心前瞻性队列研究纳入韩国三家转诊医院的1177例低风险甲状腺微小乳头状癌患者,患者自行选择主动监测(755例)或立即手术(422例)。中位随访41.4个月,706例可分析主动监测患者中复合进展率为9.6%,2年和5年进展估计分别为5.3%和14.2%,未发生远处转移;诊断年龄<30岁、男性、肿瘤≥6 mm与进展独立相关。

要点

  • 主动监测期间复合进展率为9.6%(68/706),5年进展估计为14.2%。
  • 诊断年龄<30岁(OR 2.86)、男性(OR 2.48)、肿瘤≥6 mm(OR 1.89)与进展独立相关。
  • 主动监测期间未发生远处转移。

核心结论

  • 韩国人群中低风险甲状腺微小乳头状癌主动监测期间进展率较低,但略高于其他人群既往报告。
  • 主动监测下疾病进展的危险因素包括较年轻年龄、男性和较大肿瘤尺寸。

研究设计与样本

  • 多中心前瞻性队列研究,纳入韩国三家转诊医院的患者,参与者自行选择进入主动监测组或立即手术组。
  • 共纳入1177例符合条件的甲状腺微小乳头状癌患者(女性919例,78.1%),中位年龄48岁(范围19-87)。
  • 755例(64.1%)选择主动监测,422例(35.9%)接受手术;主动监测组中706例(女性537例,76.1%)至少接受两次超声检查并纳入分析。
  • 所有患者每6-12个月接受颈部超声监测疾病进展。

主要发现

  • 在41.4个月(标准差16.0)的随访期间,163例(23.1%)主动监测患者接受了手术。
  • 复合结局定义的进展见于9.6%(68/706)的患者,2年和5年进展估计分别为5.3%和14.2%。
  • 肿瘤单维度增大3 mm定义的进展率为5.8%(41/706),两维度增大2×2 mm定义的进展率为5.4%(38/706),新发淋巴结转移为1.3%(9/706),新发甲状腺外侵犯为0.4%(3/706)。
  • 主动监测期间未发生远处转移。
  • 多因素logistic回归分析显示,诊断年龄<30岁(OR 2.86;95%CI 1.10-7.45)、男性(OR 2.48;95%CI 1.47-4.20)、肿瘤大小≥6 mm(OR 1.89;95%CI 1.09-3.27)为独立显著因素。

关键数值与推荐

  • 进展判定标准:单维度肿瘤增大3 mm,或两维度增大2×2 mm,或新发甲状腺外侵犯,或新发淋巴结转移;复合结局采用以上四项标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Active surveillance (AS) is an alternative to thyroidectomy for the management of low-risk papillary thyroid microcarcinoma (PTMC). However, prospective AS data collected from diverse populations are needed. Methods: This multicenter prospective cohort study enrolled patients from three referral hospitals in Korea. The participants were self-assigned into two groups, AS or immediate surgery. All patients underwent neck ultrasound every 6-12 months to monitor for disease progression. Progression under AS was evaluated by a criterion of tumor size increment by 3 mm in one dimension (3 mm), 2 mm in two dimensions (2 × 2 mm), new extrathyroidal extension (ETE), or new lymph node metastasis (LNM), and a composite outcome was defined using all four criteria. Results: A total of 1177 eligible patients with PTMC (919 female, 78.1%) with a median age of 48 years (range 19-87) were enrolled; 755 (64.1%) patients chose AS and 422 (35.9%) underwent surgery. Among 755 patients under AS, 706 (female 537, 76.1%) underwent at least two ultrasound examinations and were analyzed. Over a follow-up period of 41.4 months (standard deviation, 16.0), 163 AS patients (23.1%) underwent surgery. Progression defined by the composite outcome was observed in 9.6% (68/706) of patients, and the 2- and 5-year progression estimates were 5.3% and 14.2%, respectively. The observed progression rates were 5.8% (41/706) and 5.4% (38/706) as defined by tumor size enlargement by 3 mm and 2 × 2 mm, respectively, and 1.3% (9/706) and 0.4% (3/706) for new LNM and ETE, respectively. No distant metastases developed during AS. In multivariate logistic regression analysis examining variables associated with progression under AS, age at diagnosis <30 years (odds ratio [OR], 2.86; 95% confidence interval [CI], 1.10 - 7.45), male sex (OR, 2.48; 95% CI, 1.47 - 4.20), and tumor size ≥6 mm (OR, 1.89; 95% CI, 1.09 - 3.27) were independently significant. Conclusions: The progression of low-risk PTMC during AS in the Korean population was low, but slightly higher than previously reported in other populations. Risk factors for disease progression under AS include younger age, male sex, and larger tumor size. Clinical trial registration: Clinicaltrials.gov NCT02938702.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lee EK, Moon JH, Hwangbo Y, et al. Progression of Low-Risk Papillary Thyroid Microcarcinoma During Active Surveillance: Interim Analysis of a Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma in Korea. Thyroid. 2022. PMID: 36205563. doi:10.1089/thy.2021.0614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。